Epidermal Growth Factor-mediated Prevention of Renal Ischemia/Reperfusion Injury

Manuel E Caballero,1 José L Calunga,2 Ernesto Barber,3 Eduardo Cruz,4 Pedro López-Saura,1 Eduardo Boix,5∗ Jorge Berlanga1

1Center for Genetic Engineering and Biotechnology, PO Box 6162, Havana 10600, Cuba. E-mail: jorge.berlanga@cigb.edu.cu 2Center for Ozone Therapy, Havana, Cuba. 3Renal Physiology Laboratory, Havana School of Medicine. 4Biochemistry Department, Center for Biological Control, Food and Drug Faculty, University of Havana. 5Department of Pathology, Pediatric Hospital “Juan M. Márquez”.

ABSTRACT

The potential benefit of the epidermal growth factor (EGF) intervention in preventing renal damages due to ischemia/reperfusion, has not been examined so far. Female Wistar rats were randomly assigned (N = 10/group) to receive EGF at 500 or 750 µg/kg, or saline solution by a catheter via the femoral vein. An additional sham ischemized was included. Thirty minutes after treatment, bilateral renal ischemia was established for the same time, followed by 3 h of reperfusion. Post-reperfusion renal functionality was examined by determining the clearance of inulin and aminohippuric acid. The urinary volume for 10 min after reperfusion time was registered. Blood and kidney samples were collected for biochemical and histopathological studies. Intrarenal levels of malondialdehyde (MDA), as well as the activity of the enzymes phospholipase A2 (PLA2) and catalase were determined. EGF showed to significantly enhance diuresis (P < 0.05) in a dose-dependent manner. Accordingly, EGF significantly reduced renal tissue damages (P < 0.01). Renal functionality was preserved (P < 0.01) in the animals treated with the highest EGF dose. Intrarenal levels of MDA and the activity of the enzymes PLA2 and catalase were reduced. EGF exerts a prophylactic nephroprotective effect against the deleterious consequences of the ischemia/reperfusion episode. EGF contributed to preserve the morphological and functional integrity of the organ in a dose-dependent manner. Protection seems to be at least partially mediated by an anti-liperoxidative mechanism.

Keywords: EGF, ischemia, kidney, reperfusion

Biotecnología Aplicada 2000;17:161-165

INTRODUCTION

Central organ systems including heart, gut, brain, and kidney are particularly sensitive to ischaemia followed by reperfusion (I/R). Renal I/R injury alone imposes a significant burden on the healthcare system, as it not only restricts function and availability of donor kidneys for transplantation, but also a serious clinical complication of circulatory shock in sepsis, burns, etc [1].

Epidermal growth factor (EGF) is a well-known mitogen for a variety of epithelial and mesenchymally-derived cells [2]. EGF is also a potent cytoprotective and reparative polypeptide growth factor for the gastrointestinal mucosa [3] and other tissues when they are exposed to injurious factors or necrogenic agents [4].

The salutary effects of the systemic administration of exogenous EGF on different experimentally reproduced renal injury models, have been previously documented. Humes et al. [5] first demonstrated that EGF accelerates the regenerative process and the renal functional recovery following induction of ischemic renal injury in rats. An independent group subsequently confirmed that the EGF intervention accelerated functional recovery in rats affected by ischemic tubular necrosis [6]. Further experiments


RESUMEN

El factor de crecimiento epidérmico previene los daños renales asociados al episodio de isquemia/reperfusión. Aún no se ha estudiado el efecto potencial del recimiento epidérmico (FCE) en la prevención de los daños renales que se producen por isquemia/reperfusión (I/R). Se asignaron aleatoriamente ratas hembras Wistar (N = 10/grupo) al tratamiento con dosis de 500, 750 µg/kg de FCE o a solución salina. Se incluyeron ratas laparatomizadas y no sometidas a isquemia. A los 30 min después del tratamiento, se provocó isquemia renal bilateral durante el mismo tiempo, seguido de 3 h de reperfusión. El funcionamiento renal se determinó mediante el cálculo del nivel de aclaramiento de marcadores administrados. Se registró el nivel de diuresis espontánea durante 10 min después de la reperfusión. Se obtuvieron muestras sanguíneas y renales para estudios bioquímicos e histopatológicos. Se determinó la concentración renal de malondialdehído (MDA), así como la actividad de las enzimas fosfolipasa A2 (PLA2) y catalasa. El tratamiento con FCE estimuló la diuresis (P < 0,05) y redujo (P < 0,01) los daños estructurales. El funcionamiento renal se mantuvo en los rangos fisiológicos en los animales tratados con la dosis superior. Los niveles intrarrenales de MDA y la actividad de las enzimas fueron menores en los grupos tratados con FCE (P < 0,01). Una administración profiláctica de FCE ofrece protección renal en el episodio de I/R de una forma dependiente de la dosis. Este efecto parece estar mediado, al menos parcialmente, por un mecanismo anti-liperoxidante.

Palabras claves: FCE, isquemia, reperfusión, riñón

Corresponding author

© Elfos Scientiae 2000
also showed that EGF therapy reduced mortality in rats with ischemic renal injury [7]. Other experimental models based on the nephrotoxic effect of some chemicals confirmed that exogenously administered EGF promoted a rapid relining of the injured renal tubular epithelium, and shortened the recovery time of renal excretory function [8, 9].

Acute renal injury causes a reduced expression of pre-proEGF mRNA, while the concentration of bio-

logically active EGF rises seven to tenfold in the proximal tubules at the site of injury. This increase in local EGF availability is followed by a burst of tubular cells proliferation, and seems to be crucial for their regeneration [10, 11].

Exogenously-administered EGF provokes renal cell protection and, thus, may act as a survival factor when it is applied prior or during damage induction [12]. Subcutaneously injected EGF showed to reduce to 50% the number of apoptotic epithelial tubular cells in rats subjected to bilateral ureteral obstruction [13]. We have demonstrated that a single systemic administration of EGF significantly reduces glomerular tuft collapse, and tubular and interstitial damages, while enhances the creatinim clearance in a chemically-induc-

ted multiple organ failure model [14]. We next obtained similar findings in severely scalded rodents (Berlanga J., submitted). In both experimental sce-

narios, I/R is acknowledged as an important patho-

physiological event for the onset of kidneys and other internal organs deterioration. The present experiment is, therefore, an attempt to definitively elucidate if a single EGF intervention confers renal protection in morphological and functional terms, when applied prior the induction of a controlled I/R episode.

**Materials and Methods**

**Animals**

Female Wistar rats (200–220 g of weight) were ob-

tained from the National Center for Laboratory Ani-

mal Production (CENPALAB, Havana, Cuba). The animals were allocated in a certified room with con-

trolled environmental conditions at the animal facility of the Center for Genetic Engineering and Biotechnol-

gy (CIGB, Cuba). Rats were fed with standard com-

mercial diet and water ad libitum. This experiment was conducted in compliance with the standard guide-

lines of the Animal Ethics Committee of the CIGB.

**EGF and treatment**

Commercially available human recombinant EGF was obtai-

ned from Heber Biotec SA, Havana, Cuba. The peptide was reconstituted in normal saline solution (IMELA, Havana, Cuba), filter-sterilized (0.22 μm; Sartorius, Goettingen, Germany) and kept at 4 °C until use. Rats were randomly assigned to four groups (N = 10). Animals from groups I and II received EGF at 500 or 750 μg/kg, respectively. Animals from group III received normal saline solution. A fourth non-treated sham ischemized group of rats was in-

cluded. These animals were laparotomized, catheter-

ized, but their kidneys were not subjected to ischemia. EGF and the normal saline solutions (1 mL total vol-

ume) were slowly administered via a catheter inserted in the right femoral vein. Thirty minutes later, the

ischemic episode was initiated. A thermal pad was used to maintain animals’ temperature.

**Renal ischemia/reperfusion**

Once the animals were anesthetized (sodium pento-

barnal, Roig-Farma, Spain), surgically instrumented and treated, bilateral renal ischemia was provoked by clamping the renal pedicles with non-traumatic microclamps, placed at the same time for 30 min as previ-

ously described [15]. Afterwards, spontaneous reperfusion was allowed for a controlled period of 3 h.

**Renal functional assessment**

Renal functionality was examined by determining the renal plasma blood flow (RPF) and the glomerular filtration rate (GFR) by means of plasma clearance of p-amino-hippurate (PAH) and inulin (In), respectively, as described [16]. Briefly, plasma was saturated with PAH (Merck, Germany) and In (BDH Chemicals, England). The solution of both substances (2 mg PAH + 20 mg In/100 mL of normal saline) was con-

tinuously infused during the reperfusion time by a peri-

staltic pump through the left femoral vein at a constant rate of 150 μL/min, after an initial loading with 800 μL containing 12 mg/mL PAH and 2 mg/mL In. After 15–20 min of reperfusion, blood was collected by car-


diac puncture, whereas at the same time urine was di-

rectly collected from the bladder. The concentration of the PAH and In markers was determined in cad-

mium sulfate-deproteinated plasma and urine, using for PAH the photocolorimetric technique described by Smith and Tinkelstein [17]. Inulin was measured by the direct method of resorcinol without alkaline treat-

ment [18]. Plasmatic markers (PM) Clearance (C) was calculated as described [16] and shown:

\[ C = \frac{U_{\text{fio}} \times [PM]}{[PM]} \]

where,

\[ U_{\text{voc}} \] volume of excerted urine per minute

\[ [PM] \] and \[ [PM] \] respective urinary and plasmatic concentrations of each marker (PAH or In). Data are expressed as mL/min/g of body weight.

**Urinary excretion**

Diuresis was studied according to a previous descrip-

tion of the model [16]. The volume of excerted urine during 10 min after the reperfusion time was collected via a bladder catheter once the meatum was ligated. Total urine volume is expressed in µL/10 min.

**Biochemical determinations**

Kidneys were excised during autopsy, and rapidly divided lengthways, so that one half was immediately

divided lengthways, so that one half was immediately

fuged (Hitachi, Japan) at 8500 x g for 30 min. The

frozen kidneys were homogenized (Janke and Kunkel GmbH and Co, Staufen, Germany) at 4 °C in 50 mM KCl/histidine buffer pH 7.4, 1:10 (w/v), and centri-

fuged (Hitachi, Japan) at 8500 x g for 30 min. The supernatants were used to determine the renal tissue concentrations of malondialdehyde (MDA) as one of the end products of ischemia-derived oxidative stress. MDA was determined by the thiorbbituric acid method [19] and the results were expressed as nmol/mg of protein. The activity of the enzymes catalase and phospholipase A (PLA) was determined as described

4. Berlanga J, Caballero M, Prats P, Lopez-Saura P, Playford RJ. Reflections over the effect citoprotector del factor de cre-


7. Miller SB, Martin DR, Kissane J, Hammer-

man MR. Insulin-like growth factor I acceler-

ates recovery from ischemic acute tubu-


8. Coimbra TM, Geilinsky DA, Humes HD. Epidermal growth factor accelerates renal repair in mercuric chloride nephro-


9. Morin NL, Laurent G, Nonclerc D, Toubeau G, Heuson-Steinnan JA, Berg-


10. Schaudies RR, Johnson PJ. Multiple EGF containing proteins in rat kidney: increased soluble EGF following ischemia is accompanied by a decrease in membrane-associated EGF. Am J Physiol 1995;264:


13. Kennedy WA, Buttyn R, Garcia Mon-


14. Berlanga J, Caballero E, Losado J, López-Saura P, Ramirez D, Playford RJ. Epidermal growth factor prevents multi-


15. Fervenza FC, Tanny T, Robbin R. Re-

sponse to the intrarenal insulin-like growth factor-I axis to acute ischemic injury and treatment with growth hor-

mone and epidermal growth factor. Kid-


16. Barber E, Menendez S, Leon OS, 

Barber MA, Merino N, Calunga JL, et al. Prevention of renal injury after in-

duction of warm ischemia by rats sub-

mitted to warm ischemia. Mediators of Inflammation 1999;8:37–41.

17. Smith HW, Tinkelstein N. The renal cleavage of substituted histidine acid derivatives and other aromatic acids in dog and man. J Clin Invest 1945;24:

388–91.


19. Toubeau G, Heuson-Steinnon JA, Berg-


F806–11.
by León et al. [20] and Hotter et al., respectively [21]. Enzymatic activities were expressed as U/g of protein. The Coomassie blue method was used for protein quantitation [22].

**Renal histopathology**

The kidneys were fixed in 10% buffered formalin, paraffin embedded, 5-µm sectioned and stained with hematoxyline and eosine. The blind examination of specimens allowed the identification of the most frequent histopathological changes, so that their incidence (expressed as %) was determined in every group. The parameters studied involved glomerular, tubular and interstitial changes, and were categorized as: (I) number of collapsed glomeruli (quantified on each section at a constant magnification x10), (II) presence of cortical and medullary hemorrhagic foci, (III) severe tubular damage (manifested by cellular detachment, apoptotic-like images given by chromatin condensation at the periphery of the nucleus, karyorrhexis, karyolysis, cellular coagulation), and (IV) severe interstitial damage (characterized by a marked edema, tubular distortion, eosinophilic deposits, and inflammatory infiltrate). The histopathological parameters used in this work are in line with those reported by other authors for similar models or clinical situations of renal I/R [15, 23].

**Statistical analyses**

Firstly, normality of data distribution was analyzed by the Kolmogorov-Smirnov test. Post-reperfusion diuresis was compared by the non-parametric Mann-Whitney U test because data were not normally distributed. One-way ANOVA followed by the Duncan’s multiple rank test, were used to compare the GFR and the RPF indexes, as well as the intrarenal biochemical parameters (MDA, PLA₂, and catalase). The incidence of each histopathological parameter of damage was also compared by ANOVA and Duncan’s test. A significance value of \( P < 0.05 \) was established for all the tests.

**Results**

**Post-reperfusion diuresis**

The ischemic episode significantly impaired diuresis \( (P < 0.05) \) in the control group receiving saline solution, as compared to values registered in sham ischemic animals (Table 1). EGF intervention influenced diuresis in a dose-dependent manner. Animals receiving the first dose level increased the diuresis in relation to the control group, although this difference was not statistically demonstrated \( (P = 0.056) \). Rats receiving the highest EGF dose, however, preserved their diuresis \( (P = 0.02) \), which was noted slightly enhanced (not significantly) in relation to the sham ischemic group.

**Morphological renal changes**

The histopathological examination revealed clear differences among the groups, and they all involved the kidney’s structures. The main damage of the glomeruli consisted in tuft collapse (Figures A and B), accompanied by a relative enlargement of the Bowman’s capsule. Occasionally, the Bowman’s space appeared obliterated by an eosinophilic foamy material. Other glomeruli exhibited hemorrhagic content. Thus, the number of damaged glomeruli was quantified on each section. Exogenously administered EGF significantly reduced the number of collapsed glomeruli as compared to the control group \( (P = 0.04) \) (Table 2). The quantification of hemorrhagic foci on the cortical and medullary segments demonstrated that this damage was also significantly \( (P < 0.01) \) reduced by both EGF doses I and II. Glomeruli are relatively intact and tubules appear as normal (5 µm section, hematoxiline and eosine staining, magnification x 25).

**Table 1. Post-reperfusion diuretic output.**

<table>
<thead>
<tr>
<th>Groups</th>
<th>Glomerular collapse</th>
<th>Cortical hemorrhage</th>
<th>Medullary hemorrhage</th>
<th>Parenchymal hemorrhage</th>
<th>Severe tubular damage</th>
<th>Severe interstitial damage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose I</td>
<td>17.03 ± 1.43**</td>
<td>22.2</td>
<td>55.5</td>
<td>11.1</td>
<td>33.3</td>
<td>11.1</td>
</tr>
<tr>
<td>Dose II</td>
<td>19.68 ± 0.68**</td>
<td>0</td>
<td>37.5</td>
<td>0</td>
<td>25</td>
<td>0</td>
</tr>
<tr>
<td>Control</td>
<td>28.33 ± 2.35</td>
<td>77.7*</td>
<td>88.8*</td>
<td>66.6*</td>
<td>100*</td>
<td>88.8*</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD, and were compared by a one-way ANOVA and Duncan’s multiple rank test. \( *P < 0.01; **P < 0.05; \) both EGF doses vs. saline-treated control. Except for glomerular collapse, significant differences were observed in the remaining parameters when EGF doses were compared, all \( P < 0.05 \). Significance established value was \( P < 0.05 \).

**Figure A**) Saline control-derived injured kidney. Glomerular collapse associated to relative enlargement of the Bowman’s capsule can be easily distinguished. In addition, a great number of tubules exhibiting epithelial flattening can be seen (5 µm section, hematoxiline and eosine staining, magnification x 25). B) EGF-attenuated renal structural damages. This is a representative image of an animal receiving EGF dose II. Glomeruli are relatively intact and tubules appear as normal (5 µm section, hematoxiline and eosine staining, magnification x 25). (See color picture in page 214).

**Table 2. Percent of animals with renal histopathological changes per group.**

<table>
<thead>
<tr>
<th>Groups</th>
<th>Glomerular collapse</th>
<th>Cortical hemorrhage</th>
<th>Medullary hemorrhage</th>
<th>Parenchymal hemorrhage</th>
<th>Severe tubular damage</th>
<th>Severe interstitial damage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose I</td>
<td>17.03 ± 1.43**</td>
<td>22.2</td>
<td>55.5</td>
<td>11.1</td>
<td>33.3</td>
<td>11.1</td>
</tr>
<tr>
<td>Dose II</td>
<td>19.68 ± 0.68**</td>
<td>0</td>
<td>37.5</td>
<td>0</td>
<td>25</td>
<td>0</td>
</tr>
<tr>
<td>Control</td>
<td>28.33 ± 2.35</td>
<td>77.7*</td>
<td>88.8*</td>
<td>66.6*</td>
<td>100*</td>
<td>88.8*</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD, and were compared by a one-way ANOVA and Duncan’s multiple rank test. \( *P < 0.01; **P < 0.05; \) both EGF doses vs. saline-treated control. Except for glomerular collapse, significant differences were observed in the remaining parameters when EGF doses were compared, all \( P < 0.05 \). Significance established value was \( P < 0.05 \).
also significantly increased (1.5-fold) with respect to the sham ischemic group. In these animals the renal genotype, lase was significantly elevated (3 and 1.5-fold respectively) in relation to the magnitude of the EGF dose assayed.

Renal functional tests
As previously described, renal functional assessment was based on the calculated clearance of PAF and In, as indicators of the RPF and of the GFR, respectively. Table 3 illustrates that ischemia/reperfusion impaired RPF although in a non-significant manner (P = 0.056) in animals receiving saline solution, whereas the intensity of the GFR was drastically reduced (more than twofold), as compared to the values calculated for sham ischemized rats (P < 0.01). The first EGF dose (500 µg/kg) was ineffective in preserving neither the RPF nor the GFR. In fact, the values registered in this group were undistinguishable from those found in the saline control. The second EGF dose, however, significantly (P < 0.01) preserved the renal physiology, as judged by the RPF values registered in this group. The incidence of this damage was drastically reduced (more than 75%) in the animals treated with the largest EGF dose level, whereas in the animals treated with the largest EGF dose, these changes were not detected (for both EGF doses, P < 0.01). EGF treatment seemed to reduce the mediulary inflammatory infiltrate and the recruitment of vessel luminal neutrophils. In general terms, the integrity of the renal tissue architecture was in relation to the magnitude of the EGF dose assayed.

Biochemical determinations
As shown in Table 4, as a consequence of the I/R episode the activity of the enzymes PLA₂ and catalase was significantly elevated (1.5-fold) with respect to non-ischemic rats (P < 0.01). With the EGF intervention, a significant reduction (P < 0.01) in the three parameters studied was detected as compared to saline control group. Moreover, the most important reduction of the three biochemical parameters was found in the animals treated with the largest EGF dose, which supports the relevance of this dose in terms of morphologic and functional preservation.

Discussion

The histological examination revealed the salutary effects of the EGF treatment, expressed by a more defined tissue architectural integrity and viability as compared to saline controls. EGF intervention ameliorated glomerular, tubular, and interstitial damages in a dose-dependent fashion. The effect of the second EGF dose was particularly relevant because it prevented the onset of cortical hemorrhages in all the animals studied. Hemorrhage prevention by EGF in this context may theoretically represent the attenuation of endothelial damage and dysfunction in response to locally generated free radicals, or the contribution of EGF to maintenance of the RPF autoregulation mechanisms. In correspondence with the morphological findings, rats treated with 750 µg/kg EGF exhibited a normal renal functioning as judged by the RPF and GFR indexes. In saline controls, however, GFR was reduced to more than 60%. In other words, in these animals ARF was prevented by extrapolating the definition that ARF is a rapid deterioration of kidney function with at least a 50% decrease in GFR [27]. Failure in regaining a normal RPF after ischemia has been attributed to the prevalence of the vasoconstrictor mediator endothelins, which also regulates the GFR [27]. In theory, EGF could preserve GFR by pharmacological use of EGF in the settings of ischemic or toxic acute renal injury accelerates regeneration and is therefore beneficial [for review see reference 24]. The potential benefits of the EGF prophylactic effects by virtue of its cytoprotective properties have remained much less explored, despite a tissue-protective intervention is frequently and urgently demanded in the therapeutic armamentarium [25]. This experiment has shown the prophylactic impact of a single instillation of exogenous EGF by affording renal protection and attenuating the consequences of the ischemic episode in a dose-dependent manner, when the growth factor was administered before creating an ischemic environment.

Despite this model represents a mild ischemia time, kidney morphology and physiology were disrupted. Thus, in this context, renal damage may be explained by the fact that 30 min of ischemia is sufficient to deplete more than 90% of cellular ATP [26], and by the prolonged reperfusion allowed.

Table 3. Renal functional tests.

<table>
<thead>
<tr>
<th>Groups</th>
<th>RPF (ml/min/100 g body weight)</th>
<th>GFR (ml/min/100 g body weight)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham ischemic</td>
<td>2.22 ± 0.42</td>
<td>0.6 ± 0.22</td>
</tr>
<tr>
<td>Saline control</td>
<td>1.60 ± 1.31</td>
<td>0.26 ± 0.27</td>
</tr>
<tr>
<td>EGF dose I</td>
<td>1.57 ± 1.52</td>
<td>0.26 ± 0.28</td>
</tr>
<tr>
<td>EGF dose II</td>
<td>2.87 ± 0.60**</td>
<td>0.67 ± 0.13**</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD. *Significant reduction in glomerular filtration rate (GFR) in the saline-treated control vs. the value obtained from the sham ischemic animals, P = 0.002. **Difference between rats treated with 750 µg/kg EGF vs. the saline control, P = 0.0037 for renal plasma flow (RPF) and P = 0.005 for GFR. Comparisons were performed by a one-way ANOVA and Duncan’s test. The significance established was P < 0.05. RPF and GFR are expressed in ml/min/100 g body weight.

Table 4. Biochemical determinations in renal tissue.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Catalase (U/g protein)</th>
<th>Phospholipase A₂ (nmol/mg protein)</th>
<th>MDA (nmol/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham ischemic</td>
<td>627.5 ± 31.6</td>
<td>28.6 ± 4.99</td>
<td>551.9 ± 83.8</td>
</tr>
<tr>
<td>Saline-control</td>
<td>1598.3 ± 40.64*</td>
<td>87.19 ± 5.03*</td>
<td>935 ± 46.84*</td>
</tr>
<tr>
<td>EGF-dose I</td>
<td>1035.3 ± 58.69**</td>
<td>59.02 ± 2.57**</td>
<td>797.79 ± 23.19**</td>
</tr>
<tr>
<td>EGF-dose II</td>
<td>799.2 ± 31.72**</td>
<td>41.96 ± 4.93**</td>
<td>587 ± 42.07**</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD. Ischemia/reperfusion significantly elevated the renal levels of malondialdehyde (MDA), and the activity of enzymes catalase and PLA₂ in saline-treated vs. sham ischemic rats, all P < 0.001. A significant reduction of the markers was observed in animals receiving EGF, compared to saline control, all P < 0.001. Comparisons were performed by a one-way ANOVA and Duncan’s test. The significance established was P < 0.05. MDA is expressed in nmol/mg of protein. Enzyme activity is expressed in U/g of protein.


164 Biotecnología Aplicada 2000; Vol.17, No.3
interfering with the endothelins-mediated vasoconstrictor mechanism, or alternatively, by favoring the production of vasodilator agents such as nitric oxide (NO) by endothelial cells [28]. Other lines of evidence show that mucosal hyperemia sustains the EGF-mediated gastroprotection [for review see 29], whereas an increased mucosal blood flow is induced and controlled by locally synthesized NO [30]. As aforementioned, the 500 µg/kg EGF dose did not show to attenuate renal functional failure, even when the kidney morphology appeared relatively well preserved. This disparity is not surprising and has been extensively recognized in humans affected by ARF. An explanation for this states that many sublethally injured tubular cells, while appearing intact, can still contribute to tubular leakiness and obstruction in the process of injury [31].

In the plethoric pathophysiology of ischemic renal injury, the generation of reactive oxygen species (ROS) by vascular, inflammatory and epithelial cells plays a critical role [32], whereas these cells are also the primary target of ROS toxicity [33]. ROS generation is particularly relevant in renal pathology since the medulla physiologically remains in a markedly hypoxic state rendering the organ very prone to hypoperfusion [34]. In this experiment, I/R provoked a significant intrarenal accumulation of the reactive by-product MDA as an increase in the enzymatic activity of catalase and PLA₂. A global interpretation of the data obtained from the EGF-treated animals indicates that EGF contributed to reduce the generation of ROS and lipoperoxidative metabolites in a dose-dependent manner. The twofold reduction in catalase and PLA₂ activity in animals receiving the highest EGF dose, suggests that EGF somehow prevented the formation or facilitated the neutralization of hydrogen peroxide, and that also prevented the over-production of inflammatory mediators (i.e., platelet-activating factor [PAF]), which may derive from free fatty acids and lysophospholipids released by PLA₂ [35]. In other experimental systems, EGF has shown a marked antioxidant activity by stimulating the production of superoxide dismutase (SOD) [36]. Our group is currently investigating if SOD overexpression is part of the EGF-triggered protective mechanisms in renal I/R.

In vitro and in vivo evidences converge to support our findings that the cytoprotective ability of EGF is expressed in reducing lethal tissue damages and the lipid peroxidation process. These findings include gastric stress ulcers [37], ozone cytotoxicity on airway epithelial cells [38], carbon tetrachloride-mediated liver necrosis [39], apoptosis by hyperoxia in cultured neurons [40], and cerebral injury by ischemia [41]. Finally, the absence of EGF in the culture medium of tubular epithelial cells results in apoptosis emphasizing the survival and renotrophic qualities of this polypeptide [42]. This work is possibly the first experimental demonstration of the beneficial effects of using exogenous EGF as a prophylactic resource in ischemic renal damage. Clinical experience has considered that prophylactic interventions with cytoprotective drugs are an urgent imperative need, particularly for those processes involved in the slippery slope of multiple organ dysfunction. Meanwhile, the systemic use of EGF alone or in combination with other polypeptide growth factor awaits clinical assessment in subjects prone to clinical or surgical ischemic episodes.